Volume 2.43 | Oct 31

Pulmonary Cell News 2.43 October 31, 2013
Pulmonary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
Human iPS Cell-Derived Alveolar Epithelium Repopulates Lung Extracellular Matrix
Researchers generated a relatively homogeneous population of alveolar epithelial type II (AETII) and type I (AETI) cells from human induced pluripotent stem cells (iPSCs) that had phenotypic properties similar to those of mature human AETII and AETI cells. They used these cells to explore whether lung tissue can be regenerated in vitro. [J Clin Invest] Full Article
View On-Demand Webinar: Optimized Differentiation of Bronchial Epithelial Cells
PUBLICATIONS (Ranked by impact factor of the journal)
MicroRNA 4423 Is a Primate-Specific Regulator of Airway Epithelial Cell Differentiation and Lung Carcinogenesis
Researchers used next-generation sequencing of small RNAs in the airway to identify microRNA 4423 (miR-4423) as a primate-specific microRNA associated with lung cancer and expressed primarily in mucociliary epithelium. The endogenous expression of miR-4423 increases as bronchial epithelial cells undergo differentiation into mucociliary epithelium in vitro, and its overexpression during this process causes an increase in the number of ciliated cells. [Proc Natl Acad Sci USA] Abstract | Full Article

Role of NADPH Oxidase in Mediating Vesicant-Induced IL-6 Secretion in Human Airway Epithelial Cells
Scientists evaluated the role of redox signaling in regulating nitrogen mustard (HN2)-induced, epidermal growth factor receptor (EGFR)-mediated interleukin (IL)-6 secretions in primary cultured normal human bronchial epithelial cells in air-liquid interphase. HN2-induced EGFR phosphorylation and IL-6 secretion in normal human bronchial epithelial cells were inhibited both by the antioxidant N-acetyl-L-cysteine and the flavoprotein inhibitor, diphenyleneiodonium chloride. [Am J Respir Cell Mol Biol] Abstract

Induction of RGS2 Expression by Long-Acting ß2-Adrenoceptor Agonists and Glucocorticoids in Human Airway Epithelial Cells
In human bronchial epithelial BEAS-2B cells, regulator of G protein signaling (RGS) 2 mRNA and protein was synergistically induced in response to combinations of long-acting ß2-adrenoceptor agonist plus glucocorticoid. Equivalent responses occurred in primary human bronchial epithelial cells. [J Pharmacol Exp Ther] Abstract | Full Article

Tanshinone IIA Inhibits Lipopolysacharide-Induced MUC1 Overexpression in Alveolar Epithelial Cells
Researchers investigated the effects of Tanshionone IIA on lipopolysaccharide-induced acute lung inflammation, as well as its relationship to mucin 1 (Muc1) expression in mouse lung and MUC1 in human alveolar epithelial cells. [Am J Physiol Cell Physiol] Abstract

Alveolar Epithelial Cells (A549) Exposed at the Air-Liquid Interface to Diesel Exhaust: First Study in TNO’s Powertrain Test Center
Scientists investigated the feasibility of exposing human lung epithelial cells at the air-liquid interface to complete diesel exhaust generated by a heavy-duty truck in the state-of-the-art TNO powertrain test center. [Toxicol In Vitro] Abstract


YEATS4 Is a Novel Oncogene Amplified in Non-Small Cell Lung Cancer that Regulates the p53 Pathway
Overexpression of YEATS4 abrogated senescence in human bronchial epithelial cells. Conversely, RNAi-mediated attenuation of YEATS4 in human lung cancer cells reduced their proliferation and tumor growth, impairing colony formation and inducing cellular senescence. [Cancer Res] Abstract | Full Article

MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Due to MET or AXL Activation
Researchers investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in non-small cell lung cancer cells with acquired resistance to gefitinib or erlotinib. [Cancer Res] Abstract

HSP-90 Inhibitor Ganetespib Is Synergistic with Doxorubicin in Small Cell Lung Cancer
Using small cell lung cancer (SCLC) cell lines, scientists demonstrated that ganetespib was much more potent than 17-allylamino-17-demethoxygeldanamycin, a geldanamycin derivative. Ganetespib inhibited SCLC cell growth via induction of persistent G2/M arrest and Caspase 3-dependent cell death. [Oncogene] Abstract

FBXW7 Mediates Chemotherapeutic Sensitivity and Prognosis in NSCLC
Scientists focused on F-box and WD repeat domain containing-7 (FBXW7), a E3 ubiquitin ligase, that regulates the degradation of MCL1, Myc, Cyclin E, and TOP2A. Mechanistic study of non-small cell lung cancer (NSCLC) cell lines with silenced FBXW7 revealed enhanced MS-275 sensitivity and Taxol resistance. [Mol Cancer Res] Abstract

Downregulation of G3BPs Inhibits the Growth, Migration and Invasion of Human Lung Carcinoma H1299 Cells by Suppressing the Src/FAK-Associated Signaling Pathway
Researchers report that both transient and stable knockdown of G3BP suppressed the growth, migration and invasion capability of human lung carcinoma H1299 cells. Moreover, downregulation of G3BP significantly inhibited the phosphorylation of Src, FAK and ERK, and the levels of NF-?B were also markedly decreased in H1299 cells. [Cancer Gene Ther] Abstract

PneumaCult™-ALI Medium for Bronchial Epithelial Cells: Watch the Video
17q21 Locus and ORMDL3: An Increased Risk for Childhood Asthma
Genetic variations in the 17q21 locus are strongly associated with childhood non-allergic asthma. Expression of the 17q21 genes orosomucoid like 3 (ORMDL3) and gasdermin B is affected by these disease-associated variants. However, until recently no functional connection of the protein products coded for by these genes with asthma was known. [Pediatr Res] Abstract

H2AX a Promising Biomarker for Lung Cancer: A Review
This review will focus on the possible applications of H2A variant (H2AX) as a key regulator of DNA damage response in lung cancer and as a biomarker of: sensitivity of lung tumors to chemotherapy and radiotherapy, treatment with PARP inhibitors, bystander effect, multistep lung carcinogenesis, environmental smoking, and chemical genotoxicity, chemoprevention, prognosis, and also as therapeutic targets in lung cancers. [ Cancer Invest] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
Merck Announces Presentation of Interim Data from Phase IB Study of MK-3475, Investigational anti-PD-1 Immunotherapy, in Previously-Treated Patients with Non-Small Cell Lung Cancer (NSCLC)
Merck announced the presentation of interim data from a Phase 1B trial evaluating MK-3475, an investigational anti-PD-1 immunotherapy, in patients with previously-treated NSCLC. [Press release from Merck discussing research presented at the 15th World Conference on Lung Cancer, Sydney] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.
BREO® ELLIPTA™ Now Available in the U.S. for the Treatment of COPD
GlaxoSmithKline plc and Theravance, Inc. announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), is now available to pharmacies throughout the U.S. [PR Newswire Association LLC] Press Release

U.S. FDA Grants Orphan Drug Designation for KaloBios’ KB001-A in Treatment of Cystic Fibrosis Patients
KaloBios Pharmaceuticals, Inc. announced that the U.S. Food & Drug Administration (FDA) has granted the company orphan drug designation for KB001-A, an anti-PcrV monoclonal antibody fragment, for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. [KaloBios Pharmaceuticals, Inc.]
Press Release

Pulmatrix Announces Positive Results from Initial Stage of Phase IB Clinical Study of PUR0200 in COPD Patients
Pulmatrix announced the successful completion and positive results of the first part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate PUR0200. [Pulmatrix, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW AACR-IASLC: Conference on Lung Cancer
January 6-9, 2014
San Diego, United States

Visit our events page to see a complete list of events in the pulmonary cell community.
NEW PhD Studentship – Epithelial Surfaces in the Lung (University of East Anglia)

NEW Postdoctoral Scientist – Prognostic Biomarkers in Lung Cancer and Mesothelioma (Medical Research Council)

Postdoctoral Research Associate – Molecular Mechanisms of Endothelial Permeability, Vascular Inflammation, and Pulmonary Injury (University of Illinois)

Postdoctoral Research Fellow – Emphysema (University College Dublin)

Postdoctoral Research Associate – Airway Innate Defense and Biology (University of North Carolina – Chapel Hill)

Senior Postdoctoral Fellow – Mechanisms of Lung Injuries (University of Texas Health Science Center at Tyler)

Postdoctoral Fellow – Lung Research (Brigham & Women’s Hospital – Harvard Medical School)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Pulmonary Cell News: Archives | Events | Contact Us